Scarica l'app Stockscreener
27.79
1.03%
-0.29
Dopo l'orario di chiusura:
27.88
0.09
+0.32%
Precedente Chiudi:
$28.08
Aprire:
$28.5
Volume 24 ore:
912.37K
Relative Volume:
0.40
Capitalizzazione di mercato:
$3.55B
Reddito:
$-665.00K
Utile/perdita netta:
$-150.11M
Rapporto P/E:
-18.44
EPS:
-1.5071
Flusso di cassa netto:
$-124.53M
1 W Prestazione:
-5.76%
1M Prestazione:
-19.43%
6M Prestazione:
+85.89%
1 anno Prestazione:
+109.10%
Intervallo 1D:
$27.64
$28.81
Intervallo di 1 settimana:
$27.55
$30.14
Portata 52W:
$10.83
$41.14
Amylyx Pharmaceuticals Inc Stock (AMLX) Company Profile
Nome
Amylyx Pharmaceuticals Inc
Settore
Telefono
617-682-0917
Indirizzo
55 CAMBRIDGE PARKWAY, CAMBRIDGE
Compare AMLX vs TAK, TEVA, HLN, ZTS, UTHR
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
AMLX
Amylyx Pharmaceuticals Inc
|
27.79 | 3.76B | -665.00K | -150.11M | -124.53M | -1.5071 |
TAK
Takeda Pharmaceutical Co Adr
|
17.86 | 60.23B | 29.91B | 1.30B | 3.49B | 0.4056 |
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
39.53 | 45.71B | 17.53B | 1.58B | 444.18M | 1.3457 |
HLN
Haleon Plc Adr
|
8.80 | 40.72B | 14.54B | 2.22B | 2.58B | 0.4871 |
ZTS
Zoetis Inc
|
69.69 | 29.36B | 9.51B | 2.64B | 2.14B | 6.0361 |
UTHR
United Therapeutics Corp
|
541.70 | 20.39B | 3.17B | 1.29B | 1.01B | 27.09 |
Amylyx Pharmaceuticals Inc Stock (AMLX) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-03-03 | Iniziato | Stifel | Buy |
| 2025-07-10 | Ripresa | Goldman | Buy |
| 2025-06-24 | Iniziato | Guggenheim | Buy |
| 2025-06-17 | Iniziato | Citigroup | Buy |
| 2025-05-30 | Iniziato | TD Cowen | Buy |
| 2025-04-07 | Aggiornamento | Mizuho | Neutral → Outperform |
| 2024-11-18 | Aggiornamento | Robert W. Baird | Neutral → Outperform |
| 2024-10-23 | Aggiornamento | BofA Securities | Neutral → Buy |
| 2024-03-18 | Downgrade | Mizuho | Buy → Neutral |
| 2024-03-11 | Downgrade | Leerink Partners | Outperform → Market Perform |
| 2024-03-11 | Downgrade | Robert W. Baird | Outperform → Neutral |
| 2024-03-08 | Downgrade | Evercore ISI | Outperform → In-line |
| 2024-03-08 | Downgrade | Goldman | Buy → Neutral |
| 2024-01-03 | Iniziato | Robert W. Baird | Outperform |
| 2023-12-12 | Iniziato | Deutsche Bank | Buy |
| 2023-07-24 | Aggiornamento | Goldman | Neutral → Buy |
| 2023-03-31 | Iniziato | Mizuho | Buy |
| 2023-01-05 | Iniziato | BofA Securities | Buy |
| 2022-05-25 | Iniziato | Citigroup | Buy |
| 2022-04-01 | Downgrade | Goldman | Buy → Neutral |
Mostra tutto
Amylyx Pharmaceuticals Inc Borsa (AMLX) Ultime notizie
Stifel reiterates Amylyx stock rating on avexitide confidence - Investing.com
Amylyx Pharmaceuticals, Inc. Sued for Securities Law Violations – Investors Should Contact Levi & Korsinsky Before April 9, 2024 to Discuss Your Rights – AMLX - ACCESS Newswire
Amylyx at Stifel 2026 virtual cardiometabolic forum: avexitide gains By Investing.com - Investing.com Canada
Amylyx Pharmaceuticals, Inc. (AMLX) Stock Price, News, Quote & History - Yahoo! Finance Canada
Amylyx Pharmaceuticals, Inc. (AMLX) stock price, news, quote and history - Yahoo Finance Singapore
Amylyx Pharmaceuticals (AMLX) Short Interest & Short Float | Updated Sep 2026 - MarketBeat
Amylyx Pharmaceuticals to Present at the Stifel 2026 Virtual Cardiometabolic Forum - BioSpace
Amylyx Pharmaceuticals Stock Price Forecast. Should You Buy AMLX? - StockInvest.us
Amylyx Pharmaceuticals, Inc. (AMLX) Stock Analysis: Tapping into a 24.82% Upside Potential - DirectorsTalk Interviews
Amylyx Pharmaceuticals (AMLX) Signs Avexitide Supply Deals, Is The Stock Fully Priced? - Simply Wall Street
Amylyx (AMLX) Rallies +3.86% as Bulls Target $35.58 2026-09-17Sell Signal Alerts - careplusvn.com
Have Amylyx Pharmaceuticals Insiders Been Selling Stock? - webull.com
AMLX: Avexitide achieved strong efficacy in PBH, with NDA filing and launch preparations underway - TradingView
AMLX: Avexitide achieved robust efficacy in PBH, with NDA filing and commercial launch targeted for 2027 - tradingview.com
Amylyx (AMLX) CMO auto-sells 10,028 shares for taxes - stocktitan.net
Automatic tax sale by Amylyx (NASDAQ: AMLX) CFO - Stock Titan
Amylyx (NASDAQ: AMLX) co-CEO sells shares to cover taxes - Stock Titan
Amylyx Pharmaceuticals (AMLX) co-CEO sells shares to cover tax bill - Stock Titan
Automatic tax-share sale by Amylyx (AMLX) legal chief - Stock Titan
Amylyx Pharmaceuticals Insiders Sold Shares Worth Over $1.9M - TradingView
Amylyx Pharmaceuticals, Inc. Sued for Securities Law Violations – Investors Should Contact Levi & Korsinsky for More InformationAMLX - ACCESS Newswire
Amylyx Pharmaceuticals, Inc. Sued for Securities Law Violations – Investors Should Contact Levi & Korsinsky Before April 9, 2024 to Discuss Your RightsAMLX - ACCESS Newswire
Amylyx Pharmaceuticals | 144: Notice of proposed sale of securities pursuant to Rule 144 - Moomoo
Automatic stock sale for taxes ahead at Amylyx Pharmaceuticals (AMLX) - Stock Titan
Amylyx (NASDAQ: AMLX) insider schedules automatic 60K-share sale - Stock Titan
Amylyx (NASDAQ: AMLX) officer lines up tax-driven share sale - Stock Titan
Amylyx (AMLX) insider schedules automatic tax share sale - Stock Titan
Automatic Amylyx (AMLX) stock sale set to cover taxes - Stock Titan
After two decades at Alkermes, a biotech CFO joins Tortugas’ board - Stock Titan
Amylyx Pharmaceuticals Inks Avexitide Supply Deals With Bachem and Polypeptide; $30 Million Upfront to Reserve Capacity - TradingView
Amylyx Pharmaceuticals | 8-K: Current report - Moomoo
Amylyx Pharmaceuticals to Present at the 24th Annual Morgan Stanley Global Healthcare Conference - Business Wire
The Manufacturers Life Insurance Company Makes New $679,000 Investment in Amylyx Pharmaceuticals, Inc. $AMLX - MarketBeat
Amylyx Pharmaceuticals (AMLX) director exercises 50K stock options - Stock Titan
Is GLP-1 Stock Amylyx Still a Buy After Skyrocketing 247%? - Yahoo Finance
Amylyx Pharmaceuticals (AMLX) Is Down 10.1% After Strong Phase 3 Avexitide Data And $500M Equity Raise – Has The Bull Case Changed? - webull.com
Should Eli Lilly Investors Be Worried About a Threat From Amylyx? - Yahoo Finance
Oracle Stock Stands Out Among Healthy High Growth Potential Picks - sahmcapital.com
Oracle Stock And Palantir Shares Stand Out For High Growth Investors - Sahm
Guggenheim Maintains Amylyx Pharmaceuticals(AMLX.US) With Buy Rating, Raises Target Price to $57 - Moomoo
Guggenheim raises Amylyx stock price target on financing, trial data By Investing.com - Investing.com Australia
Oracle Stock And Two Other Growth Names With Stronger Balance Sheet Appeal - sahmcapital.com
Amylyx (AMLX) Quarter in Focus: EPS Misses Its Estimate in the Available Record; Price Move: Shares Move 2.52% Lower in the Latest ReadingRetail Earnings Report - careplusvn.com
LifeSci Capital Maintains Amylyx Pharmaceuticals(AMLX.US) With Buy Rating, Maintains Target Price $44 - Moomoo
Why Amylyx Pharmaceuticals Blasted Nearly 79% Higher This Week - Yahoo Finance
Amylyx (AMLX) Faces a Binary Phase 3 Test. Can Avexitide Rebuild the Company? - Yahoo Finance
MercadoLibre Stock And 2 High Growth Picks With Strong Balance Sheets - Sahm
Amylyx Pharmaceuticals (AMLX) co-CEO nets 60K performance shares - Stock Titan
Amylyx (NASDAQ: AMLX) CMO’s stock award lifts stake to 288,092 shares - Stock Titan
Amylyx Pharmaceuticals Announces Equity Offering to Fund Avexitide - TipRanks
Amylyx Pharmaceuticals Announces $471.7 Million Public Stock Offering Priced at $35.50 Per Share - Kalkine Media
Amylyx Pharmaceuticals Inc Azioni (AMLX) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Amylyx Pharmaceuticals Inc Azioni (AMLX) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| FRATES JAMES M | Chief Financial Officer |
Sep 10 '26 |
Sale |
32.36 |
10,810 |
349,821 |
233,625 |
| Mazzariello Gina | Chief Legal Officer |
Sep 10 '26 |
Sale |
32.46 |
9,536 |
309,506 |
190,838 |
| Klee Justin B. | Co-Chief Executive Officer |
Sep 10 '26 |
Sale |
32.18 |
30,464 |
980,263 |
3,613,056 |
| Cohen Joshua B | Co-Chief Executive Officer |
Sep 10 '26 |
Sale |
32.19 |
30,464 |
980,504 |
3,613,123 |
1.15%
5.19%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):